Cabozantinib,Nivolumab,Ipilimumab
Exelixis,bms
['triplet,(-triplete)', 'cosmic-313']
today's #esmo22 presidential symposium (4:30 local time in paris) features dana-farber's toni choueiri, md, ( ) on cosmic-313 #kidneycancer study comparing triplet therapy to immunotherapy combo.
cc: press release here 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090